



ASX RELEASE

24 January 2018

Current and past elite sportspeople successfully treated with PPS

Highlights:

- A growing number of past and present elite sportspeople are being treated by their doctors with Pentosan Polysulfate Sodium (PPS) for osteoarthritis (OA).
- PPS is neither a steroid or opioid, allowing for its approval in professional sports and more importantly, it is non-addictive and free of debilitating side effects.
- OA affects as much as 13% of the world's population with more than 75% of patients reporting the need for additional symptomatic treatment.¹
- In CY2018, Paradigm's arthritis program will be reporting on two Phase 2 randomised double-blind placebo-controlled clinical trials investigating PPS in treating arthritis.
- In CY2018, Paradigm will also be continually reporting on Real World Evidence data of people with OA being treated with PPS.

Paradigm Biopharmaceuticals Ltd (ASX: PAR) reports a growing number of past and present elite sportspeople are being successfully treated by their doctors with PPS for osteoarthritis (OA) under the Therapeutic Goods Administration's (TGA's) Special Access Scheme (SAS) - demonstrating the unmet medical need in treating the condition.

OA affects in excess of 30 million people in the United States alone, which is expected to rise significantly with an aging population, representing a blockbuster opportunity for Paradigm.²

¹ Matthews GL and Hunter DJ, [Expert Opin Emerg Drugs](#). 2011 Sep; 16(3):479-91. doi: 10.1517/14728214.2011.576670. Epub 2011 May 4.

² <https://www.arthritis.org/Documents/Sections/About-Arthritis/arthritis-facts-stats-figures.pdf>

Sports which involve running, pivoting, twisting and turning such as football, rugby, soccer and basketball put participants at a higher risk of developing OA and developing OA at an earlier age compared to the general population.

Interestingly, sportpeople are at a much higher risk of developing OA, especially at earlier stages in life. The University of Nottingham recently conducted a survey of 1,207 male ex-footballers and 4,085 men in the general population in the United Kingdom. It was the first large-scale cross-sectional study to compare outcomes of knee pain, radiographic OA and the requirement for knee arthroplasty (knee replacement) in ex-footballers to men in the general population. The prevalence of all knee outcomes was almost two to three times higher in ex-footballers³.

About OA and injectable PPS

Injectable PPS is not currently registered in Australia but it is registered in four of the seven major global pharmaceutical markets. In those markets, injectable PPS is registered as an antithrombotic agent. In Australia, injectable PPS for human use is not currently available for sale. It is only available by treating physicians applying for its use in patients via the TGA's SAS - Category B.

About Paradigm's clinical trial

For any enquiries about Paradigm's osteoarthritis clinical trial please visit our website (<http://www.paradigmbiopharma.com/clinical/join-our-clinical-trial>) or email: info@paradigmbiopharma.com

CORPORATE ENQUIRIES:

Paul Rennie
Director & CEO
Paradigm Biopharmaceuticals Ltd
E: prennie@paradigmbiopharma.com
M: +61 437 778 300

MEDIA ENQUIRIES:

Gabriella Hold
Media and Capital Partners
E: gabriella.hold@mcpartners.com.au
M: +61 411 364 382

Justin Kelly
Media and Capital Partners
E: justin.kelly@mcpartners.com.au
M: +61 408 215 858

³ Fernandes GS, et al. Br J Sports Med 2017; 0:1–7. doi:10.1136/bjsports-2017-097503